Reduction of cardiovascular morbidity and mortality by antihypertensive combination-therapy in patients with typ 2 diabetes mellitus;Senkung der kardiovaskulären morbidität und mortalität durch antihypertensive kombinations-therapie bei patienten mit typ 2 diabetes mellitus

Wiener Medizinische Wochenschrift

Volumn 152, Issue 9-10, 2002, Pages 210-214

  Abrahamian, Heidemarie ^a   Prager, R ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

Author keywords

Antihypertensive agents; Cardiovascular morbidity; Diabetes mellitus; Hypertension

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; METOPROLOL; NISOLDIPINE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART DEATH; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 17644448599     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-258X.2002.01119.x     Document Type: Review

References (27)

1. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidon: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
2. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: Results of prospective designed overviews of randomised trials
3. th Annual Advanced Postgraduate Course
4. Morbidity and mortality in patients randomised to double- blind treatment with a long-acting calcium-channel blocker or diuretic in the Inter-national Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment(INSIGHT)
5. What does STOP-2 tell us about management of hypertension?
6. Influence of diabetes and type of Hypertension on the response to antihypertensive treatment
7. Hypertension and diabetes: New therapeutic options
8. Optimisation of antihypertensive treatment by crossover rotation of four major classes
9. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension
10. Clinical trials in isolated systolic hypertension
11. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
12. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
13. Effect of angiotensin-converting-enzyme inhibition comparde with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP)randomised trial
14. Effects of ramipril on cardiovascular and microvascular autcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
15. The effect of Urapidil and Ramipril on hyperglycemia in streptozotocin diabetic rats
16. Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?
17. Randomised controlled trial of dual blockade of renin-angiotensin system with hypertension, microalbuminuria and non-insulin dependent diabetes: Candesartan and lisinopril microalbuminuria study
18. Therapeutic benefits of ACE-Inhibitors and other antihypertensive drugs in patients with type 2 diabetes
19. Meta-analysis of hypertension trials in diabetic patients
20. Health outcomes associated with calcium antagonists and other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials
21. Therapeutic benefits of ACE-inhibitors and other drugs in patients with type 2 diabetes mellitus
22. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on cardiovascular events in high-risk patients
23. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39)
24. The HOPE study and diabetes (Correspondence)
25. What cardiologists need to know about diabetes
26. Diabetes mellitus and coronary heart disease
27. Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) study